Happy hump day, !

This week we dive into the Pharma R&D market, with total spending projected to skyrocket to $366B by 2030.

The women’s health tech market is booming, currently valued at $38.9B, it is forecast to grow by 12.6% to $112.3B by 2033 with tech driven startups and better regulatory landscape driving the growth.

The Healthcare API market is increasingly growing, mainly fueled by patient-driven digital health solutions and AI adoption. It is expected to reach a staggering $337B market value by 2030

-Healthcare 150 Team

Pharma R&D Spending Goes from Big to Bigger

Pharma R&D spending has nearly doubled since 2016, hitting $306B in 2024 and projected to reach $366B by 2030. AI-driven drug discovery, biotech advances, and regulatory hurdles are driving costs up, but companies are betting big on specialized therapies and rare disease treatments.

The drug pipeline is also booming—22,825 drugs in development, a 280% jump since 2001. Oncology still leads (38% of new candidates), but other areas, like neurology, are catching up.

Meanwhile, the U.S. remains the pharma R&D powerhouse, but China is closing the gap fast, adding 1,627 new drug candidates in 2023 alone. With spending surging and competition heating up, the question isn’t whether innovation will continue—it’s who will profit most from it.

Want to learn more?

Premium Perks

Since you are an Executive Subscriber, you get access to all the full length reports our research team makes every week. Interested in learning all the hard data behind the article? If so, this report is just for you.

Want to check the other reports? Access the Report Repository here.

The Healthcare API Market: A $337B Opportunity by 2030

The healthcare API market is booming, projected to grow from $103.86B in 2021 to $337.01B by 2030,a staggering increase fueled by interoperability demands, AI adoption, and patient-driven digital health solutions.

Why the surge? APIs are the backbone of modern healthcare, enabling seamless EHR integration, real-time data sharing, and AI-powered diagnostics. As regulations push for greater data transparency, healthcare providers and insurers are investing heavily in secure, scalable API infrastructure to improve efficiency and patient outcomes.

With cloud adoption rising and digital health innovation accelerating, the big question is: Will the industry keep pace with demand, or will outdated systems hold back progress?

In partnership with Range

Optimize Your Wealth Like You Optimize Deals.

Most people think wealth management is just about investments.

But why do we only focus on the market while ignoring taxes, equity, estate planning, and cash flow?

Your wealth is more than just your portfolio—it’s your entire financial picture. That’s why Range built a modern, all-in-one platform that helps high-earning households manage everything from investments to tax strategy, real estate, and equity compensation—all for a single flat fee.

After years of working with top executives, self-employed professionals, and investors frustrated with piecemeal solutions, Range developed a smarter way to manage wealth. Their innovative model combines fiduciary advisors with a state-of-the-art platform, delivering seamless, personalized financial guidance that actually fits your life.

And even if you already have a financial planner, you’d be surprised how much Range can optimize your strategy. They take care of the complex moving parts, so you can focus on what really matters—growing and protecting your wealth.

Ready for a smarter approach to wealth management? 

Book a complimentary demo today and see how Range helps you unlock the full potential of your money.

Femtech’s Big Bet: A $112B Fast Growing segment

The Women’s Health Tech market is hitting the accelerator. According to Data Intelligence, the global Femtech market—valued at $38.9B in 2024—is projected to triple to $112.3B by 2033, growing at a 12.6% CAGR. Not bad for a sector that was once an afterthought in VC boardrooms. What’s driving the boom? Rising demand for personalized health solutions, better regulatory backing, and an influx of tech-driven startups. 

Key players like Flo, Natural Cycles, and Allara are leading the charge in reproductive health, fertility tracking, and digital diagnostics. Still, with women’s health finally getting overdue attention (and funding), expect more deal flow and M&A action in this space.

In partnership with Range

Optimize Your Wealth Like You Optimize Deals.

Your wealth is more than just your portfolio—it’s your entire financial picture. That’s why Range built a modern, all-in-one platform that helps high-earning households manage everything from investments to tax strategy, real estate, and equity compensation—all for a single flat fee.

Ready for a smarter approach to wealth management? 

Book a complimentary demo today and see how Range helps you unlock the full potential of your money.

Mallinckrodt + Endo: A $6.7B Pharma Lifeline or Just Delayed Pain?

Two embattled drugmakers, one big merger, and a surprise assist from tariffs, Mallinckrodt and Endo are linking up in a $6.7 billion deal. 

Both companies have been dragged down by opioid litigation, multiple bankruptcies, and a brutal generics market, but recent trade policies favoring the U.S.-based pharmaceutical production have given them a much-needed boost.

The deal is positioned as a fresh start, aiming to create a leaner, more competitive generics powerhouse. But skeptics aren’t sold. Consolidation might buy time, but it won’t erase ongoing legal liabilities or fundamentally shift the economics of a tough industry. 

For now, investors seem optimistic, betting that strategic synergies and tariff tailwinds can stabilize these struggling players, at least for a while.

Love Healthcare150? Receive the Same Weekly Newsletter For the Private Equity Market!

PE150 delivers proprietary insights, market trends, and actionable tools for Private Equity & M&A professionals—in just one 5 minute weekly email. Subscribe now

Hepatitis B Vaccination: A Shot at Progress

In high-income countries, HepB3 coverage is holding steady, with places like the U.S. and Germany above 90%. Chile and the UAE are pushing even higher, proving that strong healthcare systems deliver.

The real action is in middle-income nations—Argentina went from 66% to 94%, a massive leap. Mexico and Ecuador also improved, while others saw only slight gains.

Then there’s the low-income group: Sudan pulled off a near-miraculous jump from 51% to 93%, but Haiti and Madagascar are still lagging. The takeaway? Vaccination rates follow the money—wealthier nations maintain high coverage, middle-income countries are catching up with targeted investments, and low-income nations struggle without sustained funding. Progress is possible, but it takes serious financial commitment.

"To be successful, you must accept all challenges that come your way. You can't just accept the ones you like"

Mike Gafka